Pancreatic Cancer Research

ResearcherUniversity of FreiburgActive in the last 2 years

Tobias Keck

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7651-6183; OpenAlex author ID A5001389547. Sources: OpenAlex.

Their work

Papers
55 (first author 2, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
222
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: none · 2014: none · 2015: 3 papers · 2016: 1 paper · 2017: 2 papers · 2018: 2 papers · 2019: 1 paper · 2020: 10 papers · 2021: 7 papers · 2022: 3 papers · 2023: 8 papers · 2024: 8 papers · 2025: 6 papers · 2026: 2 papers

Papers 50 of 55

  1. Tumor slice cultures enable rapid ex vivo profiling of patient-specific drug sensitivity in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41698-026-01663-z↗
  2. Octogenarians and Pancreatic Cancer: Is Surgery Always the Right Choice? Co-author DOI 10.3390/cancers18152423↗
  3. Minimally Invasive vs Open Left Pancreatectomy for Resectable Pancreatic Cancer: Long-Term Results of the Randomized DIPLOMA Trial. Co-author DOI 10.1001/jamasurg.2025.4054↗
  4. [Evidence for the extent and oncological benefit of lymphadenectomy for pancreatic cancer]. Co-author DOI 10.1007/s00104-024-02219-2↗
  5. An R0 resection margin does improve overall survival after PDAC resection- real-world evidence from 6.000 cases from the German Cancer Registry Group. Co-author DOI 10.1016/j.ejso.2025.109693↗
  6. [Innovations in the German Guideline for Pancreatic Cancer]. Last author DOI 10.1055/a-2529-5372↗
  7. Validation of the PANAMA Score for Survival and Benefit of Adjuvant Therapy in Patients With Resected Pancreatic Cancer after Neoadjuvant FOLFIRINOX. Co-author DOI 10.1097/sla.0000000000006650↗
  8. Perioperative outcomes in an age-adapted analysis of the German StuDoQ|Pancreas registry for PDAC. Co-author DOI 10.1186/s12893-024-02647-1↗
  9. A retrospective, multicentric, nationwide analysis of the impact of splenectomy on survival of pancreatic cancer patients. Co-author DOI 10.1007/s00423-024-03570-y↗
  10. The impact of surgical-oncologic textbook outcome in patients with stage I to III pancreatic ductal adenocarcinoma: A cross-validation study of two national re… Co-author DOI 10.1016/j.surg.2023.11.004↗
  11. The value of splenectomy during left-sided pancreatectomy for pancreatic ductal adenocarcinoma: predefined subanalysis in the DIPLOMA randomized trial. Co-author DOI 10.1093/bjs/znae236↗
  12. REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006248↗
  13. Impact of Neoadjuvant Therapy for Pancreatic Cancer: Transatlantic Trend and Postoperative Outcomes Analysis. Co-author DOI 10.1097/xcs.0000000000000971↗
  14. Surgical Outcome After Distal Pancreatectomy With and Without Portomesenteric Venous Resection in Patients with Pancreatic Adenocarcinoma: A Transatlantic Eval… Co-author DOI 10.1245/s10434-024-15932-3↗
  15. ASO Author Reflections: Distal Pancreatectomy With and Without Portomesenteric Venous Resection for Pancreatic Adenocarcinoma: A Transatlantic Evaluation of Pa… Co-author DOI 10.1245/s10434-024-16021-1↗
  16. Oncological Outcomes and Patterns of Recurrence after the Surgical Resection of an Invasive Intraductal Papillary Mucinous Neoplasm versus Primary Pancreatic D… Co-author DOI 10.3390/cancers16112016↗
  17. Minimally invasive versus open distal pancreatectomy for resectable pancreatic cancer (DIPLOMA): an international randomised non-inferiority trial. Co-author DOI 10.1016/j.lanepe.2023.100673↗
  18. Recent onset diabetes is associated with better survival in pancreatic ductal adenocarcinoma-An analysis of preoperative symptoms within the DGAV StuDoQ|Pancre… Co-author DOI 10.1016/j.surg.2023.04.042↗
  19. Overexpression of integrin alpha 2 (ITGA2) correlates with poor survival in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jclinpath-2022-208176↗
  20. Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study. Co-author DOI 10.1245/s10434-022-12387-2↗
  21. Robot-Assisted Versus Laparoscopic Distal Pancreatectomy in Patients with Resectable Pancreatic Cancer: An International, Retrospective, Cohort Study. Co-author DOI 10.1245/s10434-022-13054-2↗
  22. Molecular profiling and specific targeting of gemcitabine-resistant subclones in heterogeneous pancreatic cancer cell populations. Co-author DOI 10.3389/fonc.2023.1230382↗
  23. Elucidation of the Role of SMAD4 in Epithelial-Mesenchymal Plasticity: Does It Help to Better Understand the Consequences of DPC4 Inactivation in the Malignant… Co-author DOI 10.3390/cancers15030581↗
  24. Establishment and Molecular Characterization of Two Patient-Derived Pancreatic Ductal Adenocarcinoma Cell Lines as Preclinical Models for Treatment Response. Co-author DOI 10.3390/cells12040587↗
  25. [Incidence, Treatment and Survival in Pancreatic Cancer- Data of the Nationwide Oncological Quality Conference from a Surgical Perspective]. Co-author DOI 10.1055/a-1768-1012↗
  26. Prediction of R Status in Resections for Pancreatic Cancer Using Simplified Radiological Criteria. Co-author DOI 10.1097/sla.0000000000005433↗
  27. Concepts and Outcomes of Perioperative Therapy in Stage IA-III Pancreatic Cancer-A Cross-Validation of the National Cancer Database (NCDB) and the German Cance… Co-author DOI 10.3390/cancers14040868↗
  28. Impact of resection margin status on survival in advanced N stage pancreatic cancer - a multi-institutional analysis. Co-author DOI 10.1007/s00423-021-02138-4↗
  29. Laparoscopic versus open extended radical left pancreatectomy for pancreatic ductal adenocarcinoma: an international propensity-score matched study. Co-author DOI 10.1007/s00464-020-08206-y↗
  30. Radiological prediction of portal vein infiltration in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2020.11.015↗
  31. Minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma (DIPLOMA): study protocol for a randomized controlled trial. Co-author DOI 10.1186/s13063-021-05506-z↗
  32. Predictors for Survival in an International Cohort of Patients Undergoing Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-020-08658-5↗
  33. Postoperative Outcomes of Tangential versus Segmental Resection and End-to-end Reconstruction of the Superior Mesenterico-Portal Vein During Pancreatoduodenect… Co-author DOI 10.21873/anticanres.15329↗
  34. Organotypic Slice Cultures as Preclinical Models of Tumor Microenvironment in Primary Pancreatic Cancer and Metastasis. Co-author DOI 10.3791/62541↗
  35. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment. Co-author DOI 10.1001/jamaoncol.2020.3537↗
  36. Tumor budding as a prognostic factor in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00428-019-02719-1↗
  37. International validation and update of the Amsterdam model for prediction of survival after pancreatoduodenectomy for pancreatic cancer. Co-author DOI 10.1016/j.ejso.2019.12.023↗
  38. Computerized Medical Evidence-Based Decision Assistance System "MEBDAS®" improves in-hospital outcome after pancreatoduodenectomy for pancreatic cancer. First author DOI 10.1016/j.pan.2020.04.007↗
  39. [Indications for Surgery in Pancreatic Ductal Adenocarcinoma - Consensus Recommendations by the German Society for General and Visceral Surgery]. Co-author DOI 10.1055/a-1161-9501↗
  40. Timing But Not Patterns of Recurrence Is Different Between Node-negative and Node-positive Resected Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003123↗
  41. Neoplastic-Stromal Cell Cross-talk Regulates Matrisome Expression in Pancreatic Cancer. Co-author DOI 10.1158/1541-7786.mcr-20-0439↗
  42. Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body or Tail on Surgical and Oncological Outcome: A Propensity-Sco… Co-author DOI 10.1245/s10434-019-08137-6↗
  43. Alignment of stroma fibers, microvessel density and immune cell populations determine overall survival in pancreatic cancer-An analysis of stromal morphology. Co-author DOI 10.1371/journal.pone.0234568↗
  44. Systematic Analysis of Accuracy in Predicting Complete Oncological Resection in Pancreatic Cancer Patients-Proposal of a New Simplified Borderline Resectabilit… Co-author DOI 10.3390/cancers12040882↗
  45. The impact of preoperative biliary stenting in pancreatic cancer: A case-matched study from the German nationwide pancreatic surgery registry (DGAV StuDoQ|Panc… Co-author DOI 10.1016/j.pan.2019.09.007↗
  46. Kidney Transplantation after Extended Multivisceral Resection for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1155/2018/3757382↗
  47. Minimally Invasive Surgery of Pancreatic Cancer: Feasibility and Rationale. First author DOI 10.1159/000495324↗
  48. The Role of Fibroblasts in Pancreatic Cancer: Extracellular Matrix Versus Paracrine Factors. Co-author DOI 10.1016/j.tranon.2017.04.009↗
  49. Dietary supplementation with n-3-fatty acids in patients with pancreatic cancer and cachexia: marine phospholipids versus fish oil - a randomized controlled do… Co-author DOI 10.1186/s12944-017-0495-5↗
  50. Prognostic factors after pancreatoduodenectomy with en bloc portal venous resection for pancreatic cancer. Co-author DOI 10.1007/s00423-015-1363-2↗

Closest collaborators

The 25 strongest of 222 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ulrich Friedrich Wellner · 33 shared papers, 2015–2026 · strength 4.20
  2. Kim C. Honselmann · 22 shared papers, 2015–2026 · strength 3.25
  3. Louisa Bolm · 25 shared papers, 2016–2026 · strength 3.23
  4. Rüdiger Braun · 15 shared papers, 2021–2026 · strength 2.43
  5. Steffen Deichmann · 14 shared papers, 2015–2026 · strength 2.00
  6. Hryhoriy V. Lapshyn · 14 shared papers, 2016–2026 · strength 1.84
  7. Marc G. Besselink · 11 shared papers, 2020–2025 · strength 1.30
  8. Dirk Bausch · 12 shared papers, 2011–2021 · strength 1.03
  9. Lennart von Fritsch · 4 shared papers, 2024–2026 · strength 1.00
  10. Waldemar H. Uhl · 6 shared papers, 2019–2025 · strength 0.85
  11. Bergþór Björnsson · 6 shared papers, 2021–2024 · strength 0.81
  12. Bas Groot Koerkamp · 7 shared papers, 2020–2025 · strength 0.80
  13. Thaer S. A. Abdalla · 4 shared papers, 2024–2026 · strength 0.75
  14. Michael B. Ghadimi · 5 shared papers, 2019–2025 · strength 0.74
  15. Ekaterina Petrova · 7 shared papers, 2019–2022 · strength 0.73
  16. Adnan A. Alseidi · 7 shared papers, 2020–2025 · strength 0.71
  17. Jens Werner · 5 shared papers, 2019–2025 · strength 0.69
  18. Mohammad Abu Hilal · 7 shared papers, 2020–2024 · strength 0.67
  19. Thilo Hackert · 6 shared papers, 2020–2025 · strength 0.66
  20. Giovanni Butturini · 6 shared papers, 2020–2025 · strength 0.64
  21. Marco Del Chiaro · 5 shared papers, 2020–2025 · strength 0.61
  22. Jens Uwe Marquardt · 3 shared papers, 2023–2026 · strength 0.59
  23. Izaak Quintus Molenaar · 4 shared papers, 2023–2024 · strength 0.55
  24. Massimo Falconi · 5 shared papers, 2020–2025 · strength 0.53
  25. Ugo Boggi · 5 shared papers, 2020–2024 · strength 0.52

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.